Vivani Medical, Inc. Common Stock (DE) closed at $1.07 on Nov 4, up 1.90%, 33.1% below its 52-week closing high. Volume of 183.2K shares was 0.97× its 20-day average (close to normal).
Split-adjusted performance: -13.7% over one month, -14.4% over six months, -33.1% over one year.
Short interest was 417.1K shares at the Oct 15 settlement, down 19.7% from the prior report (1.2% of float, 2.8 days to cover).
No reported quarters with price history yet.
Percentile among 22 companies (100 = best)
Industry medians: 6-month return −0.9%, revenue growth +13.9%, net margin −44.6%, P/E 23.7×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| VANIVivani Medical, Inc. Common Stock (DE) | $1.07 | +1.90% | −14.4% | — | — | — | $96.5M | |
| STXSStereotaxis | $0.9572 | +13.55% | −50.1% | −12.8% | −62.3% | — | $95.9M | Compare |
| NRXSNeuraxis | $6.86 | +4.26% | −22.1% | +115.7% | −118.1% | — | $86.1M | Compare |
| OMOutset Medical | $4.44 | +6.99% | −1.6% | +0.7% | −56.8% | — | $83.5M | Compare |
| HYPRHyperfine | $0.7503 | +8.36% | −56.6% | +44.8% | −238.2% | — | $79.6M | Compare |
| ECORelectroCore | $8.40 | +16.18% | +26.1% | +28.0% | −32.4% | — | $75.7M | Compare |
| POCIPrecision Optics | $4.84 | +3.42% | +2.8% | +42.0% | −1.2% | — | $53.2M | Compare |
| STEXStreamex | $0.3610 | −5.00% | −64.3% | — | −9968.5% | — | $42.0M | Compare |
| ELMDElectromed | $28.01 | +4.83% | +8.0% | +11.6% | 17.5% | 20.5 | $232.1M | Compare |
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
